Legend Biotech Corp (NASDAQ:
LEGN) is one of the
13 Best Revenue Growth Stocks to Buy Right Now.
In a board shakeup last month, Legend Biotech Corp (NASDAQ:LEGN) appointed chairman and executive director of a major shareholder, GenScript, Robin Meng, as a Class III director to serve until the company’s 2026 annual general meeting, replacing outgoing director Li Zhu.
Directors Li Zhu and Yau Wai Man Philip resigned from the board, with Legend Biotech stating that the departures were not related to any dispute over operations or policies.
Earlier in the month, H. C. Wainwright lowered the price target on the stock to $50 from $60, while TD Cowen downgraded the stock to Hold from Buy, with a price target of $21.
On January 21, Legend Biotech reported preliminary net trade sales of approximately $555 million for its multiple myeloma cell therapy, CARVYKTI, for the quarter ended Dec. 31, 2025.
Legend Biotech Corp. is a clinical-stage biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications.
While we acknowledge the potential of LEGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 12 Best Software Infrastructure Stocks to Buy According to Hedge Funds and 11 Best Stocks You’ll Wish You Bought Sooner.
Disclosure: None. This article is originally published at
Insider Monkey.
